{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:44:05Z","timestamp":1747309445802},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma"],"published-print":{"date-parts":[[2002,9]]},"DOI":"10.3816\/clm.2002.n.015","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:09:54Z","timestamp":1221095394000},"page":"97-104","source":"Crossref","is-referenced-by-count":15,"title":["Gemcitabine and Its Combinations in the Treatment of Malignant Lymphoma"],"prefix":"10.3816","volume":"3","author":[{"given":"Ian","family":"Chau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2002.n.015_bib1","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2002.n.015_bib2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJM200205023461821","article-title":"Long-term follow-up of Hodgkin's disease trial","volume":"346","author":"Canellos","year":"2002","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"10.3816\/CLM.2002.n.015_bib3","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1093\/annonc\/9.suppl_5.S91","article-title":"Treatment of relapsed Hodgkin's disease: strategies and prognostic factors","volume":"9","author":"Canellos","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.V93.3.761","article-title":"Problems in Hodgkin's disease management","volume":"93","author":"Aisenberg","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.015_bib5","first-page":"769a","article-title":"BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin lymphoma study group HD9 randomized trial","volume":"98","author":"Diehl","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.015_bib6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.20.3.630","article-title":"Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial","volume":"20","author":"Horning","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2002.n.015_bib8","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.3816\/CLM.2002.n.015_bib9","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.3816\/CLM.2002.n.015_bib10","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2002.n.015_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.1999.17.1.12","article-title":"Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer","volume":"17","author":"Cardenal","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib12","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1200\/JCO.1999.17.11.3522","article-title":"Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project","volume":"17","author":"Crino","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/JCO.2000.18.1.122","article-title":"Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer","volume":"18","author":"Sandler","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2002.n.015_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/sonc.2002.31588","article-title":"Second-line treatment of ovarian cancer with single-agent gemcitabine","volume":"29","author":"Markman","year":"2002","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib16","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2001.19.15.3447","article-title":"Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial","volume":"19","author":"Bramhall","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bjc.6600446","article-title":"A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer","volume":"87","author":"Bramhall","year":"2002","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2002.n.015_bib18","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib19","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/sonc.2002.34055","article-title":"Gemcitabine and targeted therapy in metastatic breast cancer","volume":"29","author":"Qu","year":"2002","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib21","first-page":"533","article-title":"Cellular elimination of 2\u2032,2\u2032-difluorodeoxycytidine 5\u2032-triphosphate: a mechanism of self-potentiation","volume":"52","author":"Heinemann","year":"1992","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2002.n.015_bib22","first-page":"2","article-title":"Preclinical, pharmacologic, and phase I studies of gemcitabine","volume":"24","author":"Storniolo","year":"1997","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib24","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/BF00685109","article-title":"Saturation of 2\u2032,2\u2032-difluorodeoxycytidine 5\u2032-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine","volume":"27","author":"Grunewald","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CLM.2002.n.015_bib25","first-page":"3","article-title":"Gemcitabine: preclinical pharmacology and mechanisms of action","volume":"23","author":"Plunkett","year":"1996","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib26","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.1992.10.3.406","article-title":"Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study","volume":"10","author":"Grunewald","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib27","first-page":"6823","article-title":"Pharmacologically directed design of the dose rate and schedule of 2\u2032,2\u2032-difluorodeoxycytidine (Gemcitabine) administration in leukemia","volume":"50","author":"Grunewald","year":"1990","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2002.n.015_bib28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1200\/JCO.20.3.665","article-title":"Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia","volume":"20","author":"Gandhi","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib29","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.2001.02795.x","article-title":"Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma","volume":"113","author":"Dumontet","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2002.n.015_bib30","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1200\/JCO.1999.17.12.3786","article-title":"Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"17","author":"Fossa","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib31","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.1999.17.8.2625","article-title":"Gemcitabine is active in relapsed Hodgkin's disease","volume":"17","author":"Lucas","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine","volume":"113","author":"Sallah","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2002.n.015_bib33","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","article-title":"Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study","volume":"18","author":"Santoro","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1023\/A:1008307528519","article-title":"Gemcitabine for relapsed or resistant lymphoma","volume":"11","author":"Savage","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib35","first-page":"926","article-title":"Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients","volume":"85","author":"Zinzani","year":"2000","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2002.n.015_bib36","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/sj.bmt.1703363","article-title":"Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan\/GM-CSF or radiotherapy and consolidation chemotherapy","volume":"29","author":"Rapoport","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2002.n.015_bib38","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2002.08.166","article-title":"Phase I evaluation of prolongedinfusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma","volume":"20","author":"Bass","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1006478702342","article-title":"Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine","volume":"19","author":"Sezer","year":"2001","journal-title":"Invest New Drugs"},{"key":"10.3816\/CLM.2002.n.015_bib40","first-page":"157","article-title":"Rituximab and gemcitabine for elderly patients with aggressive non-Hodgkin's lymphoma","volume":"13","author":"Wenger","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib41","first-page":"158","article-title":"A combination of gemcitabine, ifosphamide and vinorelbine is active in relapsing and refractory lymphoma, both as antitumor and mobilizing regimen","volume":"13","author":"Brusamolino","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib42","first-page":"158","article-title":"Gemcitabine, dexmethasone, cisplatin (GDP) chemotherapy for relapsed or refactory non-Hodgkin's lymphoma and Hodgkin's disease","volume":"13","author":"Crump","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib43","first-page":"159","article-title":"A gemcitabine, cisplatin and dexamethazone combination in patients with multiple relapsed Hodgkin's and non-Hodgkin's lymphoma","volume":"13","author":"Emmanouilides","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib44","first-page":"159","article-title":"Combination of gemcitabine and oxaliplatin (GEMOX) in refractory and relapsed NHL","volume":"13","author":"Corazzelli","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib45","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.bjc.6690452","article-title":"Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines","volume":"80","author":"van Moorsel","year":"1999","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2002.n.015_bib46","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/0959-8049(95)00419-X","article-title":"Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts","volume":"31A","author":"Braakhuis","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLM.2002.n.015_bib47","first-page":"72","article-title":"Interaction between cisplatin and gemcitabine in vitro and in vivo","volume":"22","author":"Peters","year":"1995","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib48","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1023\/A:1008301522349","article-title":"Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors","volume":"10","author":"van Moorsel","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib49","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0959-8049(99)00004-0","article-title":"Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice","volume":"35","author":"van Moorsel","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLM.2002.n.015_bib50","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1023\/A:1008339425708","article-title":"Gemcitabine-cisplatin: a schedule finding study","volume":"10","author":"Kroep","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib51","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1200\/JCO.2000.18.11.2245","article-title":"Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients","volume":"18","author":"Nagourney","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib52","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1023\/A:1008413818569","article-title":"Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck","volume":"9","author":"Hitt","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib53","first-page":"273a","article-title":"Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma","volume":"18","author":"Tempero","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib54","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.20.3.674","article-title":"Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia","volume":"20","author":"Rizzieri","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib55","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1023\/A:1005981317532","article-title":"A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors","volume":"15","author":"Brand","year":"1997","journal-title":"Invest New Drugs"},{"key":"10.3816\/CLM.2002.n.015_bib56","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00280-002-0461-3","article-title":"Pilot study of gemcitabine (10 mg\/m(2) per min) and cisplatin","volume":"50","author":"Poplin","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CLM.2002.n.015_bib57","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib58","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib59","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.2000.18.6.1193","article-title":"Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group","volume":"18","author":"Piccart","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib60","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1023\/A:1008334215414","article-title":"Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigatororiginated compassionate-use experience","volume":"10","author":"Faivre","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib61","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/S0959-8049(97)00122-6","article-title":"Oxaliplatin\/cisplatin (LOHP\/CDDP) combination in heavily pretreated ovarian cancer","volume":"33","author":"Soulie","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLM.2002.n.015_bib62","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0959-8049(98)00007-0","article-title":"Phase II study of oxaliplatin in poorprognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques","volume":"34","author":"Monnet","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLM.2002.n.015_bib63","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1200\/JCO.2002.08.050","article-title":"Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"20","author":"Kollmannsberger","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib64","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1023\/A:1008310708853","article-title":"Preliminary results on the activity of oxaliplatin (L-OHP) in refractory\/recurrent non-Hodgkin's lymphoma patients","volume":"10","author":"Germann","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib65","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2001.03181.x","article-title":"An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non- Hodgkin's lymphoma","volume":"115","author":"Chau","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2002.n.015_bib66","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1023\/A:1012501305214","article-title":"Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma","volume":"12","author":"Machover","year":"2001","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib67","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1200\/JCO.20.6.1512","article-title":"Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study","volume":"20","author":"Louvet","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib68","first-page":"338a","article-title":"Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease (HD) treated with a modified BEACOPP regimen is probably related to the combination of gemcitabine and bleomycin","volume":"98","author":"Bredenfeld","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.015_bib69","unstructured":"Medicines Compendium 2002: Datapharm Communications LTD, 2002, 2002."},{"key":"10.3816\/CLM.2002.n.015_bib70","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00001813-199803000-00001","article-title":"Gemcitabine\u2013a safety review","volume":"9","author":"Aapro","year":"1998","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CLM.2002.n.015_bib71","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1054\/bjoc.2000.1307","article-title":"Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer\u2013a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer","volume":"83","author":"Anderson","year":"2000","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2002.n.015_bib72","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","article-title":"Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297","volume":"20","author":"Berlin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib73","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1023\/A:1012208711013","article-title":"Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatinvindesine","volume":"12","author":"Vansteenkiste","year":"2001","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib74","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<2023::AID-CNCR21>3.0.CO;2-2","article-title":"A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy","volume":"85","author":"Fung","year":"1999","journal-title":"Cancer"},{"key":"10.3816\/CLM.2002.n.015_bib75","first-page":"17","article-title":"Gemcitabine-related pulmonary toxicity","volume":"132","author":"Joerger","year":"2002","journal-title":"Swiss Med Wkly"},{"key":"10.3816\/CLM.2002.n.015_bib76","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00000421-200202000-00021","article-title":"Gemcitabine-induced pulmonary toxicity: case report and review of the literature","volume":"25","author":"Gupta","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.015_bib77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00000421-200202000-00005","article-title":"Severe pulmonary toxicity in a patient treated with gemcitabine","volume":"25","author":"Rosado","year":"2002","journal-title":"Am J Clin Oncol"}],"container-title":["Clinical Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511702561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511702561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:09:05Z","timestamp":1588918145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526965511702561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["S1526965511702561"],"URL":"https:\/\/doi.org\/10.3816\/clm.2002.n.015","relation":{},"ISSN":["1526-9655"],"issn-type":[{"value":"1526-9655","type":"print"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}